Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Fate Therapeutics, Inc. - Common Stock
(NQ:
FATE
)
2.025
+0.015 (+0.75%)
Delayed Quote
Updated: 3:52 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fate Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
4 Analysts Assess Fate Therapeutics: What You Need To Know
↗
May 14, 2025
Via
Benzinga
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
May 13, 2025
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2025
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
April 29, 2025
Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across autoimmune and cancer indications
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Gapping stocks in Monday's session
↗
April 14, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
Via
Chartmill
Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic
↗
April 14, 2025
CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus.
Via
Stocktwits
Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)
April 14, 2025
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2025
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Wednesday?
↗
March 05, 2025
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
March 05, 2025
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 04, 2025
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at Upcoming Investor Conferences
February 14, 2025
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2025
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2025
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus
December 09, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Leadership Transition
November 29, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Iris Energy, Arrowhead Pharmaceuticals, Urban Outfitters And Other Big Stocks Moving Higher On Wednesday
↗
November 27, 2024
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.
Via
Benzinga
Topics
Stocks
Fate Therapeutics to Present at Upcoming December Investor Conferences
November 26, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
November 18, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
November 18, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
November 12, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
November 09, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
November 08, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
September 12, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q2 2024
↗
August 13, 2024
FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
August 13, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
